Skip to main content
| News

Monte Rosa Therapeutics banks 96 million US dollars

28.09.2020

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful Series B financing round. Using this fresh injection of capital, the company intends to drive forward the development of its molecule degradation platform that aims to eradicate proteins regarded either as difficult to medically treat or untreatable that occur in cases of cancer, for example.

Monte Rosa Therapeutics, a biotechnology company based in Basel, has raised to a total of 96 million US dollars as part of a Series B financing round. “The company is now poised to bring forward multiple drug candidates for some of the most difficult to treat cancers and other diseases”, comments Alexander Mayweg, Chairman of the Board of Directors, in a press release.

This financing round was led by Aisling Capital, although both Versant Ventures and the existing investor New Enterprise Associates were also involved in the process. In addition, Monte Rosa can call upon a further seven new investors. “We are pleased to have the support of this strong group of investors”, states Markus Warmuth, CEO of Monte Rosa, in the press release. As a result, the company is “now well positioned to broadly develop our integrated drug discovery platform and advance multiple new therapies toward clinical development”, Warmuth adds.

With the help of the platform developed by Monte Rosa, it should now be possible to design and develop small molecule degraders even more rationally. These are designed to complement the body’s innate ability to degrade proteins. With this approach, Monte Rosa Therapeutics is aiming to eradicate proteins that cause diseases regarded either as difficult to medically treat or which are untreatable, including those present in cancers. “Many approved drugs have been developed to inhibit a protein’s function. Monte Rosa’s goal is to eliminate the protein altogether”, explains Andrew Schiff from Aisling Capital. In connection with this financing round, Schiff is set to join the Board of Directors at Monte Rosa, as will Chandra P. Leo of HBM Partners.

Monte Rosa Therapeutics has offices in the centre of Basel and labs in the Technologiepark Basel. Versant Ventures also has offices in Basel.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Space Pharmaceuticals establishes presence in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Space Pharmaceuticals establishes presence in Basel

Space Pharmaceuticals AG is strengthening the life sciences cluster in the Basel Area. At its research lab, the cheminformatics company...

Read More
NextImmune to benefit from Venture Kick financing
Basel Area Business & Innovation, Innovation, Life Sciences / biotech

NextImmune to benefit from Venture Kick financing

The startup accelerator Venture Kick is supporting NextImmune with financing in the amount of 150,000 Swiss francs. The spin-off from...

Read More
OECD impressed by the canton of Jura’s innovation system
Basel Area Business & Innovation, Innovation, Medtech, Switzerland Innovation Park

OECD impressed by the canton of Jura’s innovation system

The OECD has examined the innovation systems in place in rural areas of its member states, including the canton of...

Read More
ti&m opens branch in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest

ti&m opens branch in Basel

ti&m now has an office in Basel. With this action, the company specializing in digitization, security and innovation projects is...

Read More
What can artificial intelligence do for health?
Basel Area Business & Innovation, Digital Health, Innovation, Life Sciences / biotech, Medtech

What can artificial intelligence do for health?

Algorithms help diagnose and treat diseases, discover new drugs and personalize prevention. Thus, the potential of artificial intelligence has been...

Read More
Economic promotion agency creates 55 new jobs in Jura
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Economic promotion agency creates 55 new jobs in Jura

The economic promotion agency of the canton of Jura supported a total of 26 companies in founding, establishing a presence...

Read More
1 2 3 56

Do you have a question? We'd like to hear from you.